Celldex Q1 2021 Earnings Report
Key Takeaways
Celldex Therapeutics reported their Q1 2021 financial results. They had a total revenue of $0.7 million and a net loss of $16.5 million, or ($0.42) per share. Cash, cash equivalents and marketable securities were $176.1 million as of March 31, 2021.
CDX-0159 Phase 1b study showed 80% complete response rate in chronic inducible urticaria.
A third cohort in cholinergic urticaria was added to the CDX-0159 study.
Progress is being made advancing the bispecific platform, with promising preclinical data presented at AACR.
Cash, cash equivalents and marketable securities were $176.1 million as of March 31, 2021.
Celldex
Celldex
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2021 are sufficient to meet estimated working capital requirements and fund planned operations through 2023.